Bitscopic’s Data Research Finds Widely Available Drug Ondansetron Significantly Improves Outcomes Against COVID-19

Bitscopic Inc., in collaboration with the U.S. Department of Veterans Affairs Public Health Surveillance and Research program office (PHSR), has found that the widely available antiemetic drug Ondansetron has the potential to significantly reduce the risk of mortality, length of hospital stay, and even long-term risk of strokes and heart attacks when administered within 48 hours of a patient’s admission for COVID-19. The finding, which has been published in the journal Open Forum Infectious Diseases, was made by conducting a retrospective study of data from 13,612 patients positive for COVID-19 across 124 VA hospitals. The paper was featured as “Editors Choice” by the journal. The link to the full published paper is available here:

Get in touch